complement cascade


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.
Related to complement cascade: Membrane attack complex

complement cascade

a biochemical process involving the C1 to C9 complement proteins in which one protein interacts with another in a specific sequence called a complement pathway. C5b with C6, C7, C8, and C9 form the membrane attack complex that initiates cell lysis. Other molecules, such as C3a and C5a, act as cytokines, leading to inflammation.

complement cascade

Immunology A complex, multimolecular biologic system with ± 25 different proteins that self-assemble on cell surfaces, functioning in concert with the specific immune systems to mediate host reactions and anti-microbial defense; the coup de grâce for the hapless target cell is the polymerization of C9 on its surface, which forms a transmembrane 'doughnut' that facilitates the egress of ions, cell lysis and death. See Complement. Cf Alternate pathway, Classic pathway, Common pathway.

complement

a complex series of enzymatic proteins occurring in normal serum that are triggered in a cascade manner by, and combine with, the antibody-antigen complexes, producing lysis when the antigen is an intact cell. Complement comprises 25 to 30 discrete proteins, labeled numerically as C1 to C9, and by letters, i.e. B, D, P, etc., and with C1 being divided into subcomponents C1q, C1r and C1s. Components C3 and C5 are involved in the generation of anaphylatoxin and in the promotion of leukocyte chemotaxis, the result of these two activities being the inflammatory response. C1 and C4 are involved in the neutralization of viruses. The components also combine in various sequences to participate in other biological activities, including antibody-mediated immune lysis, phagocytosis, opsonization and anaphylaxis. The complement system is known to be activated by the immunoglobulins IgM and IgG.

alternate complement pathway, alternative complement pathway
the sequence in which complement components C3 and C5 to C9 are activated without participation by C1, C2 and C4 or the presence of an antibody-antigen complex.
complement cascade
the sequence of reactions, each being the catalyst for the next, that leads to the terminal complement pathway and cell lysis. There are two pathways for activation of C3, the 'classical' (below) and the 'alternate' (above).
classical complement pathway
the one in which all of the complement components C1 to C9 participate and is triggered by antibody-antigen complexes.
complement deficiency
various complement components may be deficient without serious effects on the host. C3 deficiency is most severe and occurs in humans, Brittany spaniels and Finnish-Landrace lambs. Increased susceptibility to infections results.
complement fixation tests
utilize antibody-antigen reaction and result in hemolysis to determine the presence of various organisms in the blood. Involves two stages. In the first, also referred to as the test system, antigen is mixed usually with serial dilutions of a test serum in the presence of complement. If the serum contains antibody, i.e. is positive, an antibody-antigen complex is formed which also binds (fixes) complement. In the second stage, also called the indicator system, sheep red blood cells coated with specific, usually rabbit anti-sheep red blood cell antibody are added. The red blood cells are said to be sensitized. If antibody was not present in stage 1, then the free complement lyses the sensitized sheep red blood cells. The basis of many serological tests including those for glanders, tuberculosis and contagious bovine pleuropneumonia. Called also Bordet-Gengou phenomenon. See also immunity.
complement regulatory proteins
a set of at least seven proteins that are present in plasma (C1 INH, C4b-binding protein, factor H and factor I) or present in cell membranes (decay-accelerating factor [DAF], membrane cofactor protein [MCP] and homologous restriction factor [HHF]) that modulate the complement proteins and protect 'innocent' bystander cells and tissues from complement damage.
terminal complement pathway
the final stages of complement activation in which C5, C6, C7, C8 and C9 are activated; common to both the alternate and classical pathways.
References in periodicals archive ?
Innate immunity of the sinonasal cavity: Expression of messenger RNA for complement cascade components and toll-like receptors.
In order to complete our research, a second test, aimed at indirectly detecting the anti-inflammatory activity, was performed on extracts impairing the complement cascade.
All of this suggests that the complement cascade is activated in the RPE/choroid and that an error in the complement pathway will not cause AMD until the age-related changes leading to increased immunological activity appear in the elderly adult.
The sCR1 protein component of the molecule is a potent inhibitor of both the classical and alternative complement cascades, which are implicated in a wide range of diseases including ischemia-reperfusion (heart attack, stroke), transplantation and chronic inflammatory diseases (arthritis, multiple sclerosis).
This complement cascade eventually results in the formation of a membrane attack complex, a multiprotein assemblage that latches onto the surface of endothelial cells, killing them directly or, more often, activating them.
The researchers suggest that stopping the complement cascade could eliminate the major cause.
That's because chicken Fc fragments can't trigger the so-called complement cascade in humans -- the intense inflammatory reaction that underlies many of the more serious symptoms of serum sickness and anaphylaxis.
By blocking the two key pathways of complement activation (the C3 and C5 convertases) early within the complement cascade, MLN2222 may reduce tissue injury in multiple organ systems, reducing the mortality and morbidity associated with CABG surgery employing CPB.
In contrast to APT070, which acts early in the complement cascade, CD59-Prodaptin(TM) interrupts the formation of the "membrane attack complex" which is responsible for killing cells.
Complement inhibitors: The Company has three products in research and development - APT070, a fragment of CR1 (complement receptor 1), which is currently in an early Phase I/II human clinical trial in rheumatoid arthritis, and, CD59 and CD55, two different complement inhibitors, which function at different sites in the complement cascade.
It acts through a variety of primitive and more advanced mechanisms, including the complement cascade, pattern recognition receptors, and macrophages to identify and target foreign intruders.

Full browser ?